JCO at 2025 ASH: Pirtobrutinib in Untreated CLL

<p><span style= "font-family: arial, helvetica, sans-serif; font-size: 12pt;"><em>JCO</em> Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia.</span></p> <p><span style= "text-decoration: underline; font-family: arial, helvetica, sans-serif; font-size: 12pt;"> <strong>TRANSCRIPT</strong></span></p> <p><em>The disclosures for guests on this podcast can be found in the show notes.</em></p> <p><strong>Dr. Jonathan Friedberg:</strong> I'm Jonathan Friedberg, editor of <a href="../../../journal/jco"><em>Journal of Clinical Oncology</em></a>, and welcome to <a href= "../../../journal/jco/podcast"><em>JCO After Hours</em></a>, where we are covering two manuscripts that were presented at the <a href= "https://www.hematology.org/meetings/annual-meeting">American Soc...